胃滯留給藥系統 (GRDDS) 外包市場報告：2030 年趨勢、預測與競爭分析

胃滯留給藥系統（GRDDS）外包趨勢與預測

全球胃滯留給藥系統（GRDDS）外包市場前景廣闊，高密度系統、可擴展給藥系統、生物黏附給藥系統和浮動給藥系統市場都有機會。預計2024年至2030年全球胃留置給藥系統外包市場將以6.7%的複合年成長率成長。該市場的主要驅動力是越來越重視以患者為中心的解決方案、不斷成長的外包需求、越來越關注局部藥物輸送以及增加對研發項目的投資。

• Lucintel 預測，以劑型分類，膠囊將在預測期內達到最高成長。
• 從市場類型來看，浮動給藥系統預計將成長最快。
• 從地區來看，由於其成熟的製藥業、強大的研發能力、強勁的市場需求和完善的醫療保健體系，預計北美在預測期內將出現最高的成長。

胃滯留給藥系統（GRDDS）外包市場的策略性成長機會

隨著製藥公司越來越注重開發針對慢性和複雜疾病的先進藥物輸送系統，胃滯留藥物輸送系統（GRDDS）外包市場提供了重要的策略性成長機會。外包的好處，例如降低成本、加快產品開發速度以及獲得專業知識，為市場成長創造了有利的環境。透過利用這些機會，受託製造廠商(CMO) 可以擴展其能力、增強其服務產品並開拓新市場。

• 擴大外包夥伴關係：製藥公司擴大與專門從事 GRDDS 的 CMO 合作，以簡化生產流程、提高效率並獲得最尖端科技。
• 對慢性病管理的需求不斷增加：糖尿病、高血壓和胃腸道疾病等慢性病的增加為開發旨在提高長期用藥依從性的專門 GRDDS 製劑提供了機會。
• 地理擴張：將外包業務擴展到醫療保健需求不斷成長的新興市場，為首席行銷長提供了在新地區獲得市場佔有率的重大機會。
• 個人化醫療：個人化、針對患者的配方的趨勢為 GRDDS 公司提供了巨大的機會，可以根據個人治療需求提供量身定做的解決方案。
• 先進技術整合：將人工智慧、資料分析等先進技術整合到GRDDS的外包流程中，可最佳化產品開發、降低成本並提高品管。

在對專業藥物輸送系統的需求、慢性病管理的進步以及對個性化醫療的需求的推動下，胃滯留藥物輸送系統（GRDDS）外包市場存在大量戰略成長機會。 CMO 可以透過專注於擴大外包夥伴關係關係、擴大地理覆蓋範圍和整合下一代技術來利用這些機會。隨著市場的成長，這些因素可能塑造胃滯留給藥系統（GRDDS）外包的未來，並開闢新的成長途徑。

胃滯留給藥系統（GRDDS）外包市場推廣因素與挑戰

胃滯留藥物輸送系統（GRDDS）外包市場受到各種促進因素​​的影響，例如對先進藥物輸送技術的需求不斷成長、慢性病管理的醫療保健需求不斷成長以及我所收到的具有成本效益的藥物製造趨勢。然而，它們也面臨一些挑戰，包括監管複雜性、高製造成本和技術限制。對於希望駕馭競爭格局並利用成長機會的公司來說，了解這些促進因素和挑戰至關重要。

市場促進因素

• 慢性病治療需求不斷增加：糖尿病和高血壓等慢性病的增加增加了對可控和持續藥物釋放的需求，從而創造了對 GRDDS 的需求。
• 外包以降低成本：製藥公司擴大外包 GRDDS 製造，以降低製造成本、提高業務靈活性並加快上市時間。
• 製劑技術的進步：生物黏附系統和控制釋放機制等藥物傳遞技術的不斷改進正在支持GRDDS應用的成長。
• 強調用藥依從性：GRDDS在提高病患長期治療順從性方面發揮重要作用，促進GRDDS在慢性病管理的應用。
• 收緊監管以實現更安全、更有效的治療方法：收緊給藥系統的監管要求正在推動創新，並不斷增加對可靠、合規的 GRDDS 解決方案的需求。

市場挑戰

• 高開發和製造成本：開發和製造GRDDS配方的複雜性可能會導致高昂的初始投資和營運成本，特別是對於中小型企業而言。
• 監管障礙：克服複雜且特定於地區的監管要求可能會延遲市場進入並增加開發成本。
• 技術複雜性：GRDDS的設計和製造需要先進的技術和專業知識，這可能會限制缺乏經驗的公司進入市場。

胃滯留給藥系統（GRDDS）外包市場是由慢性病治療需求增加、技術進步和外包的成本節約效益等因素所推動的。但它們也面臨開發成本高、監管複雜、技術障礙等挑戰。透過克服這些挑戰並利用市場促進因素和挑戰，胃滯留藥物輸送系統 (GRDDS) 外包領域的公司可以在快速發展的市場中實現持續成長和成功。

目錄

第1章執行摘要

第2章全球胃滯留給藥系統（GRDDS）外包市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球胃滯留給藥系統（GRDDS）外包市場趨勢（2018-2023）與預測（2024-2030）
• 依類型：全球胃滯留給藥系統（GRDDS）外包市場
  • 高密度系統
  • 可擴展的藥物傳輸系統
  • 生物黏附藥物傳輸系統
  • 漂浮給藥系統
  • 其他
• 按劑型分類的全球胃滯留給藥系統（GRDDS）外包市場
  • 藥片
  • 液體
  • 微球
  • 膠囊
  • 其他
• 依分銷管道分類：全球胃滯留給藥系統（GRDDS）外包市場
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第4章 2018-2030年區域市場趨勢及預測分析

• 按地區分類的胃滯留給藥系統（GRDDS）外包市場
• 北美胃滯留給藥系統（GRDDS）外包市場
• 歐洲胃滯留給藥系統（GRDDS）外包市場
• 亞太胃滯留給藥系統（GRDDS）外包市場
• 其他地區胃滯留給藥系統（GRDDS）外包市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 按類型：全球胃滯留給藥系統（GRDDS）外包市場成長機會
  • 按劑型分類的全球胃滯留給藥系統 (GRDDS) 外包市場的成長機會
  • 依分銷管道分類：全球胃滯留給藥系統（GRDDS）外包市場的成長機會
  • 按地區分類：全球胃滯留給藥系統（GRDDS）外包市場的成長機會
• 全球胃滯留給藥系統（GRDDS）外包市場新趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球胃滯留給藥系統（GRDDS）外包市場的產能
  • 全球胃滯留給藥系統（GRDDS）外包市場的併購與合資
  • 認證和許可

第7章主要企業概況

• F. Hoffmann La Roche
• Glaxo Smith Kline
• Lupin
• Pfizer
• Sun Pharma
• Ranbaxy
• Depomed

Gastroretentive Drug Delivery System Outsourcing Trends and Forecast

The future of the global gastroretentive drug delivery system outsourcing market looks promising with opportunities in the high-density system, expandable drug delivery system, bioadhesive drug delivery system, and floating drug delivery system markets. The global gastroretentive drug delivery system outsourcing market is expected to grow with a CAGR of 6.7% from 2024 to 2030. The major drivers for this market are increasing emphasis on patient-centric solutions, rising demand for outsourcing, a growing focus on localized drug delivery, and increasing investments in R&D programs.

• Lucintel forecasts that, within the dosage form category, the capsule is expected to witness the highest growth over the forecast period.
• Within this market, within the type category, the floating drug delivery system is expected to witness the highest growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the region's sophisticated pharmaceutical sector, potent R&D capacities, robust market demand, and well-established healthcare system.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Gastroretentive Drug Delivery System Outsourcing Market

The gastroretentive drug delivery system (GRDDS) market is undergoing significant transformation due to advancements in drug formulation technologies, increasing demand for sustained and controlled-release medications, and the growing trend of outsourcing in the pharmaceutical industry. As GRDDS continues to gain traction, both the drug delivery system market and the outsourcing sector are evolving. Emerging trends such as increased focus on patient-centric formulations, technological innovation, and regulatory shifts are shaping the market landscape.

• Technological Innovations in GRDDS: Innovations in polymer-based systems, pH-sensitive materials, and gastric retention devices are enhancing the performance of GRDDS, making them more effective and patient-friendly.
• Patient-Centric Drug Delivery: There is a growing emphasis on developing GRDDS formulations that cater to individual patient needs, improving drug efficacy and minimizing side effects.
• Growth in Outsourcing Services: As pharmaceutical companies seek to reduce costs and enhance operational efficiency, outsourcing GRDDS manufacturing to specialized contract service providers has been on the rise.
• Focus on Long-Term Medication Adherence: GRDDS, designed for sustained release, is increasingly used for chronic conditions, promoting better adherence to treatment regimens.
• Regulatory Advancements: Evolving regulatory frameworks around the approval and quality control of GRDDS are driving innovation and ensuring greater consistency in the market.

The gastroretentive drug delivery system outsourcing market is set to grow significantly, driven by technological advancements, the increasing demand for patient-specific solutions, and the ongoing trend of outsourcing pharmaceutical manufacturing. Innovations in GRDDS technology, coupled with evolving regulations and a focus on medication adherence, will continue to shape the future of this market. Companies that can leverage these emerging trends will likely see substantial growth and enhanced market share.

Recent Developments in the Gastroretentive Drug Delivery System Outsourcing Market

The GRDDS outsourcing market has witnessed significant recent developments as pharmaceutical companies increasingly recognize the benefits of leveraging specialized contract manufacturers for gastro retentive drug formulations. These developments reflect both technological advancements and a broader trend toward cost-efficient drug development, production, and global market expansion. The market has become more competitive, with firms focusing on innovation and regulatory compliance to meet the needs of a rapidly growing patient base.

• Advances in GRDDS Technology: Recent breakthroughs in GRDDS, such as mucoadhesive systems and bio-adhesive polymers, have improved retention times and drug release control, enhancing therapeutic outcomes.
• Growing Demand for Outsourcing: Pharmaceutical companies are increasingly outsourcing GRDDS manufacturing to reduce production costs, mitigate risks, and shorten time-to-market for new drugs.
• Increase in Regulatory Compliance: Stricter regulatory standards, especially regarding safety and efficacy, are influencing how GRDDS formulations are developed and outsourced, leading to higher-quality systems.
• Expansion of Outsourcing Networks: Leading contract manufacturing organizations (CMOs) have expanded their services globally, catering to pharmaceutical companies looking to tap into emerging markets with robust GRDDS capabilities.
• Enhanced Drug Formulation Capabilities: Companies are enhancing their GRDDS formulations with next-generation technologies like controlled-release mechanisms and targeted delivery, which significantly improve treatment for chronic diseases.

Recent developments in the GRDDS outsourcing market highlight key trends such as technological advancements, increased regulatory scrutiny, and the growing preference for outsourcing as a cost-effective solution. Companies that can innovate and adapt to these changes while maintaining a focus on regulatory compliance and patient outcomes are likely to thrive in this dynamic and rapidly expanding market.

Strategic Growth Opportunities for Gastroretentive Drug Delivery System Outsourcing Market

The GRDDS outsourcing market presents substantial strategic growth opportunities as pharmaceutical companies increasingly focus on developing advanced drug delivery systems for chronic and complex diseases. The benefits of outsourcing, such as cost reduction, accelerated product development, and access to specialized expertise, create a favorable environment for market growth. By leveraging these opportunities, contract manufacturing organizations (CMOs) can expand their capabilities, enhance service offerings, and tap into new markets.

• Expansion of Outsourcing Partnerships: Pharmaceutical companies are increasingly partnering with CMOs that specialize in GRDDS to streamline production processes, improve efficiency, and access cutting-edge technologies.
• Growing Demand for Chronic Disease Management: The rise in chronic conditions such as diabetes, hypertension, and gastrointestinal disorders presents an opportunity to develop specialized GRDDS formulations aimed at improving long-term medication adherence.
• Geographic Expansion: Expanding outsourcing operations into emerging markets with growing healthcare needs can provide CMOs with a significant opportunity to gain market share in new regions.
• Personalized Medicine: The trend toward personalized and patient-specific formulations presents a significant opportunity for GRDDS companies to tailor solutions for individual therapeutic needs.
• Integration of Advanced Technologies: The integration of advanced technologies, such as AI and data analytics, in the GRDDS outsourcing process can optimize product development, reduce costs, and improve quality control.

Strategic growth opportunities in the GRDDS outsourcing market are abundant, driven by the demand for specialized drug delivery systems, advancements in chronic disease management, and the increasing need for personalized medicine. By focusing on expanding outsourcing partnerships, geographic reach, and integrating next-generation technologies, CMOs can capitalize on these opportunities. As the market grows, these factors will help shape the future of GRDDS outsourcing and create new avenues for growth.

Gastroretentive Drug Delivery System Outsourcing Market Driver and Challenges

The GRDDS outsourcing market is influenced by a variety of drivers, such as increasing demand for advanced drug delivery technologies, growing healthcare needs for chronic disease management, and the trend toward cost-efficient pharmaceutical manufacturing. However, the market also faces several challenges, including regulatory complexities, high production costs, and technological limitations. Understanding these drivers and challenges is essential for companies looking to navigate the competitive landscape and capitalize on growth opportunities.

Market Drivers:

• Rising Demand for Chronic Disease Treatments: The increasing prevalence of chronic diseases, such as diabetes and hypertension, drives the need for controlled and sustained drug release, creating demand for GRDDS.
• Outsourcing to Reduce Costs: Pharmaceutical companies are increasingly outsourcing GRDDS manufacturing to reduce production costs, enhance operational flexibility, and speed up time-to-market.
• Technological Advancements in Drug Formulation: Continuous improvements in drug delivery technologies, including bioadhesive systems and controlled-release mechanisms, support the growth of GRDDS applications.
• Focus on Medication Adherence: GRDDS plays a crucial role in improving patient adherence to long-term treatments, thereby driving its adoption in the management of chronic conditions.
• Regulatory Push for Safer, More Effective Therapies: Stricter regulatory requirements for drug delivery systems are driving innovation and enhancing the demand for reliable and compliant GRDDS solutions.

Market Challenges:

• High Development and Manufacturing Costs: The complexity of developing and producing GRDDS formulations can result in high initial investment and operational costs, especially for smaller companies.
• Regulatory Hurdles: Navigating complex and region-specific regulatory requirements can delay market entry and increase development costs.
• Technological Complexity: The need for advanced technologies to design and manufacture GRDDS requires specialized expertise, which may limit market participation for less experienced firms.

The GRDDS outsourcing market is driven by factors such as the increasing demand for chronic disease treatments, technological advancements, and the cost-saving benefits of outsourcing. However, it also faces challenges including high development costs, regulatory complexities, and technological barriers. By overcoming these challenges and leveraging market drivers, companies in the GRDDS outsourcing space can position themselves for sustained growth and success in a rapidly evolving market.

List of Gastroretentive Drug Delivery System Outsourcing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies gastroretentive drug delivery system outsourcing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gastroretentive drug delivery system outsourcing companies profiled in this report include-

• F. Hoffmann La Roche
• Glaxo Smith Kline
• Lupin
• Pfizer
• Sun Pharma
• Ranbaxy
• Depomed

Gastroretentive Drug Delivery System Outsourcing by Segment

The study includes a forecast for the global gastroretentive drug delivery system outsourcing by type, dosage form, distribution channel, and region.

Gastroretentive Drug Delivery System Outsourcing Market by Type [Analysis by Value from 2018 to 2030]:

• High Density System
• Expandable Drug Delivery System
• Bioadhesive Drug Delivery System
• Floating Drug Delivery System
• Others

Gastroretentive Drug Delivery System Outsourcing Market by Dosage Form [Analysis by Value from 2018 to 2030]:

• Tablets
• Liquid
• Microspheres
• Capsule
• Others

Gastroretentive Drug Delivery System Outsourcing Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Gastroretentive Drug Delivery System Outsourcing Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Gastroretentive Drug Delivery System Outsourcing Market

Due to the growing need for sustained drug release formulations, the market for outsourcing Gastroretentive Drug Delivery Systems (GRDDS) is progressing significantly. This growth is driven by globalization as pharmaceutical companies enhance patient compliance and optimize therapeutic effectiveness. Outsourcing partners are focusing on innovative technologies and cost-efficient options. MRI's analysis indicates that significant in vitro and in vivo studies, as well as investments from the United States, China, Germany, India, and Japan, are helping develop market-specific novel gastroretentive formulations and manufacturing technologies.

• United States: In the U.S., the GRDDS outsourcing market is seeing an increased level of investment, particularly in offshoring GRDDS through Contract Development and Manufacturing Organizations (CDMOs). Companies are launching sophisticated formulations aimed at improving bioavailability and sustaining the rate of drug release. Collaborating with CDMOs has become a source of innovation for pharmaceutical companies, leading to the development of new types of gastroretentive systems, such as floating tablets and hydrogels, which enhance patient compliance.
• China: The GRDDS market in China is growing rapidly due to the expanding capacity of the domestic pharmaceutical industry and the rising demand for advanced drug delivery strategies. Research projects are being supported by the government, and local companies are taking the initiative to develop the next generation of vertical and lateral GRDDS systems. Domestic and foreign firms are collaborating to improve formulation methods and ensure regulatory compliance.
• Germany: Germany is well-known for its pharmaceutical development and technological advancements, and this is also evident in its GRDDS outsourcing market. Recent trends include the development of individualized therapies and focused drug delivery systems. German CDMOs are increasingly using 3D printing technology to design specific gastroretentive formulations tailored to individual patients.
• India: In India, the GRDDS outsourcing market is expanding as local pharmaceutical companies become more open to innovative approaches in drug delivery. The focus on providing cost-effective healthcare has led to the growth of more affordable GRDDS products. International partnerships are helping Indian companies acquire new competencies, enabling them to establish a global presence.
• Japan: From a regulatory standpoint, Japan's GRDDS outsourcing market is sustained by a strong focus on quality and innovation. Japanese pharmaceutical companies are investing in next-generation formulation technologies and collaborating with research institutes to develop advanced gastroretentive systems. Another emerging trend is the increasing regulatory encouragement for innovative drug delivery products, which is helping bring new products to market more rapidly.

Features of the Global Gastroretentive Drug Delivery System Outsourcing Market

Market Size Estimates: Gastroretentive drug delivery system outsourcing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Gastroretentive drug delivery system outsourcing market size by type, dosage form, distribution channel, and region in terms of value ($B).

Regional Analysis: Gastroretentive drug delivery system outsourcing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, dosage form, distribution channel, and regions for the gastroretentive drug delivery system outsourcing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gastroretentive drug delivery system outsourcing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the gastroretentive drug delivery system outsourcing market by type (high density system, expandable drug delivery system, bioadhesive drug delivery system, floating drug delivery system, and others), dosage form (tablets, liquid, microspheres, capsule, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Gastroretentive Drug Delivery System Outsourcing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Gastroretentive Drug Delivery System Outsourcing Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Gastroretentive Drug Delivery System Outsourcing Market by Type
  • 3.3.1: High Density System
  • 3.3.2: Expandable Drug Delivery System
  • 3.3.3: Bioadhesive Drug Delivery System
  • 3.3.4: Floating Drug Delivery System
  • 3.3.5: Others
• 3.4: Global Gastroretentive Drug Delivery System Outsourcing Market by Dosage Form
  • 3.4.1: Tablets
  • 3.4.2: Liquid
  • 3.4.3: Microspheres
  • 3.4.4: Capsule
  • 3.4.5: Others
• 3.5: Global Gastroretentive Drug Delivery System Outsourcing Market by Distribution Channel
  • 3.5.1: Hospital Pharmacies
  • 3.5.2: Retail Pharmacies
  • 3.5.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Gastroretentive Drug Delivery System Outsourcing Market by Region
• 4.2: North American Gastroretentive Drug Delivery System Outsourcing Market
  • 4.2.1: North American Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.2.2: North American Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others
• 4.3: European Gastroretentive Drug Delivery System Outsourcing Market
  • 4.3.1: European Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.3.2: European Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others
• 4.4: APAC Gastroretentive Drug Delivery System Outsourcing Market
  • 4.4.1: APAC Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.4.2: APAC Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others
• 4.5: ROW Gastroretentive Drug Delivery System Outsourcing Market
  • 4.5.1: ROW Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.5.2: ROW Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Type
  • 6.1.2: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Dosage Form
  • 6.1.3: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Region
• 6.2: Emerging Trends in the Global Gastroretentive Drug Delivery System Outsourcing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Gastroretentive Drug Delivery System Outsourcing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gastroretentive Drug Delivery System Outsourcing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: F. Hoffmann La Roche
• 7.2: Glaxo Smith Kline
• 7.3: Lupin
• 7.4: Pfizer
• 7.5: Sun Pharma
• 7.6: Ranbaxy
• 7.7: Depomed